AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Bone Marrow TransplantationBone MarrowTransplantation, HomologousBone Marrow CellsGraft vs Host DiseaseMyeloablative AgonistsHematopoietic Stem Cell TransplantationTransplantation ConditioningHistocompatibilityWhole-Body IrradiationTissue DonorsHematologic NeoplasmsHistocompatibility TestingBone and BonesLeukemiaGraft SurvivalTransplantation, AutologousTransplantation ChimeraImmunosuppressive AgentsHLA AntigensTreatment OutcomeAnemia, AplasticGraft RejectionLymphocyte DepletionKidney TransplantationCytomegalovirus InfectionsHematopoietic Stem CellsBusulfanRecurrenceLeukemia, Myeloid, AcuteSevere Combined ImmunodeficiencyBone Marrow PurgingCord Blood Stem Cell TransplantationBone Marrow DiseasesPeripheral Blood Stem Cell TransplantationRetrospective StudiesPrecursor Cell Lymphoblastic Leukemia-LymphomaTime FactorsCyclophosphamideOpportunistic InfectionsCyclosporineBone RemodelingImmunocompromised HostHaploidyT-LymphocytesImmunosuppressionAntilymphocyte SerumTransplantsBone Marrow ExaminationHematopoiesisAcute DiseaseCombined Modality TherapyUnrelated DonorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveRemission InductionBone Marrow NeoplasmsSurvival AnalysisLiving DonorsLymphocyte TransfusionAntigens, CD34Disease-Free SurvivalHaplotypesSiblingsMice, Inbred C57BLStem Cell TransplantationGraft vs Leukemia EffectSurvival RateMycosesHepatic Veno-Occlusive DiseaseTransplantation, IsogeneicMyelodysplastic SyndromesCytomegalovirusHematologic DiseasesBone DensityLymphoma, Non-HodgkinRadiation ChimeraGranulocyte Colony-Stimulating FactorFatal OutcomeFetal TherapiesColony-Forming Units AssayFollow-Up StudiesVidarabineTransplantationLeukemia, MyeloidHeart TransplantationGanciclovirBone ResorptionMultiple MyelomaPneumonia, ViralNuclear FamilyAspergillosisInfectionPostoperative ComplicationsAntineoplastic Combined Chemotherapy ProtocolsLeukocyte CountGraft vs Host ReactionMelphalanPolymerase Chain ReactionBlood Group IncompatibilityCell Differentiation
TransplantationDonorCyclophosphamideHematopoietic Cell TransplantStem cellsOutcomesRelapseDonorsGVHDPatientsCIBMTRUmbilical cordIntensityProcedureType of transplantBusulfanHSCTHarvestEngraftmentCohortPreventionAblativeClinicalAcuteHalf-matchedCytarabineBloodRecipientsSyndromeInfectionsHospitalGraftPredictCellsDisease
Transplantation20
  • Bone marrow (BM) continues to be the preferred source of stem cells in allogenic transplantation for nonmalignant disorders. (bvsalud.org)
  • European Society for Blood and Marrow Transplantation criteria were used to grade aGVHD. (bvsalud.org)
  • Bone Marrow Transplantation, 2013. (nih.gov)
  • Impact of Donor Age in Haploidentical-Post-Transplantation Cyclophosphamide versus Matched Unrelated Donor Post-Transplantation Cyclophosphamide Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia. (mcw.edu)
  • Real-World Data Showing Trends and Outcomes by Race and Ethnicity in Allogeneic Hematopoietic Cell Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. (mcw.edu)
  • Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. (mcw.edu)
  • Bolaños-Meade, J & Brodsky, RA 2009, ' Blood and marrow transplantation for sickle cell disease: Overcoming barriers to success ', Current opinion in oncology , vol. 21, no. 2, pp. 158-161. (johnshopkins.edu)
  • Retrospective analysis by the Center for International Blood and Marrow Transplant Research (CIBMTR): Prompt complete remission plus consolidation therapy yields improved survival after allogeneic hematopoietic cell transplantation (allo-HCT) for patients with acute myeloid leukemia (AML) receiving a myeloablative conditioning regimen and not a reduced-intensity conditioning regimen. (ascopost.com)
  • Bone marrow transplantation is a complex yet life-saving procedure that can benefit individuals with a wide range of diseases, including blood cancers like leukemia and lymphoma, aplastic anemia, immune deficiencies, and genetic disorders. (yapitahealth.com)
  • Dr. George Mathé explored the transplantation of bone marrow cells from healthy donors to treat patients accidentally irradiated at high dose, expanding the possibilities of this life-saving technique (Mathé et al. (revistadehematologia.org.mx)
  • And she's also an associated editor for the medical journal Bone Marrow Transplantation as well as a protocol officer and medical monitor for the National Heart Lung and Blood Institute, National Cancer Institute, Blood & Marrow Transplant Clinical Trials Network. (bmtinfonet.org)
  • Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. (uchicago.edu)
  • Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. (uchicago.edu)
  • Recipients of allogeneic transplantation had significantly improved overall survival compared to non-transplanted patients. (oncotarget.com)
  • Given the potential importance of MAIT cells in control of microbial infections and protection of epithelial surfaces, we investigated MAIT cell reconstitution in 43 children who underwent hematopoietic stem cell transplantation (HSCT) after myeloablative conditioning for the treatment of malignant hematological disease. (cryostem.org)
  • Currently more than 60% of ALOHT reported to the Center for International Bone Marrow Transplantation Research (CIBMTR) are performed in patients older than 40 years. (scielo.org)
  • Aim: To report our experience with ALOHT in acute myelogenous leukemia (AML), analyzing patient age at transplantation in different periods and transplant results in different age groups. (scielo.org)
  • Mild Acute Graft-Versus-Host Disease Improves Outcomes After HLA-Haploidentical-Related Donor Transplantation Using Posttransplant Cyclophosphamide and Cord Blood Transplantation. (kyoto-u.ac.jp)
  • The first evidence for the therapeutic effectiveness of natural killer (NK) cells in AML was established in a study of 57 adult patients, in which none of the 20 individuals who received haploidentical cell transplantation from a killer immunoglobulin-like receptor (KIR)-human leukocyte antigen (HLA)-mismatched donor experienced disease relapse [ 2 ]. (biomedcentral.com)
  • Stem cell transplantation is a promising strategy for therapeutic cardiac regeneration, but current therapies are limited by inefficient interaction between potentially beneficial cells (either exogenously transplanted or endogenously recruited) and the injured tissue. (regenerativemedicine.net)
Donor12
  • We analyzed 184 consecutive first matched related donor bone marrow transplants for thalassemia using G-CSF-primed bone marrow over 6 years from March 2017 to April 2023 across 2 centers in India. (bvsalud.org)
  • Haploidentical transplant -- This is a type of allogeneic transplant, in which the donor is not completely matched with the recipient. (medlineplus.gov)
  • Leukapheresis -- First, the donor is given several days of shots to help stem cells move from the bone marrow into the blood. (medlineplus.gov)
  • Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type. (mcw.edu)
  • In an attempt to expand the donor pool, several groups are beginning to explore the use of alternative sources of stem cells such as haploidentical donors and umbilical cord cell blood. (johnshopkins.edu)
  • Summary The curative potential of BMT in SCD is irrefutable, with outstanding results in children following a myeloablative conditioning regimen and a matched sibling donor transplant. (johnshopkins.edu)
  • An allogeneic stem cell transplant utilizes healthy blood stem cells from a donor to replace the diseased or damaged bone marrow. (bgsgleneaglesglobalhospitalbengaluru.com)
  • Before receiving the transplant, the patient will receive high doses of chemotherapy or radiation for destroying the diseased cells and prepare the body for the donor cells. (bgsgleneaglesglobalhospitalbengaluru.com)
  • In an allogenic transplant - compatibility with the donor is matched. (yapitahealth.com)
  • This is a phase I/Ib study of the pre-emptive treatment using related donor-derived cytokine induced memory-like (CIML) natural killer (NK) cells combined with Interleukin-2 (IL-2) for participants with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and MDS/myeloproliferative neoplasm (MDS/MPN) overlap syndrome at high risk for post-allogeneic stem cell transplant (SCT) relapse. (survivornet.com)
  • T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. (uchicago.edu)
  • Both study cohort and control are transplanted from maternal donor or collateral relatives. (biomedcentral.com)
Cyclophosphamide5
  • All patients received a conditioning backbone based on treosulfan and fludarabine, with post-transplant cyclophosphamide (PTCy) and sirolimus as graft-versus-host disease (GvHD) prophylaxis. (bvsalud.org)
  • Using mice models, Dr. Fitzhugh et al showed for the first time that sirolimus and post-transplant cyclophosphamide work synergistically to induce tolerance (Fitzhugh CD et al. (nih.gov)
  • Patients in the first cohort did not receive post-transplant (PT)-cyclophosphamide (Cy) and 3 patients were transplanted. (nih.gov)
  • In this month's Pharmacy SIG Literature Update: Impact of anti-T-lymphocyte globulin dosing on GVHD in MUD SCT, impact of MRD status before alloHCT on outcomes in secondary AML, low-dose post- transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of GVHD in MUD SCT and more. (astct.org)
  • Low-dose post-transplant cyclophosphamide (PTCy) in conjunction with anti-thymocyte globulin (ATG) appears as a potentially effective graft-versus-host disease (GVHD) prevention strategy in haploidentical hematopoietic cell transplant (haplo-HCT). (biomedcentral.com)
Hematopoietic Cell Transplant2
  • DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant. (mcw.edu)
  • Clinicopathologic features of late-onset veno-occlusive disease/sinusoidal obstruction syndrome after high dose intravenous busulfan and hematopoietic cell transplant. (uchicago.edu)
Stem cells14
Outcomes7
  • Increased access to transplant, reduced toxicity and relapse are improving patient outcomes. (bvsalud.org)
  • Correction to: Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113AML patients. (mcw.edu)
  • An important and unanswered question concerns the impact of the number of conventional AML chemotherapy induction cycles to achieve first complete remission on transplant outcomes. (ascopost.com)
  • Similarly, the outcomes of myeloablative conditioning and reduced-intensity conditioning regimens for allo-HCT and their relationship with pretransplant consolidation cycles for patients in first complete remission are also unknown. (ascopost.com)
  • This large retrospective analysis on behalf of the CIBMTR shows again that among patients eligible for allo-HCT, only one induction cycle to achieve first complete remis sion, particularly when combined with one consolidation therapy, is associated with better outcomes after myeloablative conditioning and not reduced-intensity conditioning. (ascopost.com)
  • 00:06:54): The goal of interventional clinical trials is to improve transplant outcomes through a scientific rationale. (bmtinfonet.org)
  • Neither pre-transplant clinical characteristics nor transplant characteristics are reliably predictive of GvHD outcomes. (cryostem.org)
Relapse8
  • Relapse is now the most frequent cause of transplant failure. (bvsalud.org)
  • With increased knowledge of the biological characterization of AML, better prediction of transplant risks and more profound and standardized minimal residual disease (MRD) monitoring, pharmacological, and immunological strategies to prevent relapse are been developed. (bvsalud.org)
  • Recent clinical data indicate that patients with complex karyotypes, adverse genes, and high pre-infusion minimal residual disease (MRD) by flow cytometry in the bone marrow, were at high risk of relapse after CAR T-cell therapy. (biomedcentral.com)
  • High pre-lymphodepletion lactate dehydrogenase, low pre-lymphodepletion platelet count, absence of fludarabine in lymphodepletion, persistent leukemic sequence by high throughput sequencing in bone marrow after CAR T-cell infusion, and early loss of CAR T cells have also been linked to relapse after CAR T-cell therapy. (biomedcentral.com)
  • The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or MDS and myeloproliferative neoplasm (MPN) overlap syndrome after a standard-of-care stem cell transplant. (survivornet.com)
  • Histologically or cytologically confirmed diagnosis of AML, MDS, or MDS/MPN that is at high risk for post-transplant relapse and that has measurable disease prior to transplant using MRD-depth next-generation duplex sequencing with error suppression. (survivornet.com)
  • Predictors for survival after transplant relapse. (uchicago.edu)
  • Allogeneic HCT has been widely used, while autologous HCT, which is still useful, is less prevalent because of concerns around post-transplant relapse, as well as the recently extended application of allogeneic HCT. (apbmt.org)
Donors3
  • Donors who are not related to you, yet still match, may be found through national bone marrow registries. (medlineplus.gov)
  • The second obstacle was the availability of transplant donors. (nih.gov)
  • We determined if adoptive transfer of natural killer (NK) cells from haploidentical killer immunoglobulin-like receptor (KIR)-human leukocyte antigen (HLA)-mismatched donors may prolong event-free survival in children with intermediate-risk AML who were in first complete remission after chemotherapy. (biomedcentral.com)
GVHD2
  • Adult patients (age ≥ 18) eligible for and planned to undergo a standard-of-care reduced intensity conditioning (RIC) HLA-matched related or related haploidentical allogeneic stem cell transplant using PTCY-based GVHD prophylaxis. (survivornet.com)
  • Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. (uchicago.edu)
Patients22
  • RESULTS: At transplant all patients were transfusion-dependent and had splenomegaly (median bipolar diameter by ultrasound: 20.75 cm). (bvsalud.org)
  • One of the 3 patients engrafted but lost the graft at 7 months post-transplant. (nih.gov)
  • Based on the three patients losing their grafts, stopping rules were met and the study moved to the 2nd cohort where 1 dose of Cy was given at 50mg/kg on day 3 post-transplant. (nih.gov)
  • Eight patients were transplanted in the 2nd cohort. (nih.gov)
  • This is an option for patients who can't endure a full-intensity or myeloablative allogeneic transplant. (bgsgleneaglesglobalhospitalbengaluru.com)
  • A total of 1,473 patients with a median age of 47 years received myeloablative conditioning, and 1,162 patients with a median age of 63 years received reduced-intensity conditioning. (ascopost.com)
  • About 328 patients received myeloablative conditioning, and 150 patients, reduced-intensity conditioning. (ascopost.com)
  • 01). Treatment-related mortality was similar for patients with primary induction failure vs those in first complete remission after myeloablative or reduced-intensity conditioning allo-HCT (Table 1). (ascopost.com)
  • Patients are explained thoroughly regarding Bone marrow transplant including the evaluation process, treatment side effects, cost of treatment, and associated complications. (yapitahealth.com)
  • Finding accommodation in a hotel because patients for autologous transplants need to stay for 30 days locally and allogenic transplant patients need to stay for 100 days. (yapitahealth.com)
  • Before transplant patients are instructed to stay away from sick people. (yapitahealth.com)
  • Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma. (astct.org)
  • This trial confirmed the results of other trials that demonstrated a substantial incidence of symptomatic hypotension in MM patients in the peri-transplant period following ASCT. (astct.org)
  • In a combined analysis of categorical groups, the patients in the high A- ALC group transplanted in CR1 had the best prognosis for OS and PFS and patients in the low A- ALC group transplanted in CR/PR after second-line therapy had the worse prognosis for OS and PFS. (astct.org)
  • Clinical trials for stem cell and bone marrow transplant patients are an important tool for identifying new and more effective treatments for many diseases. (bmtinfonet.org)
  • Clinical Trials are something that are frequently done for all types of cancer patients and we're going to focus a little bit more on how this works for patients going through transplants specifically. (bmtinfonet.org)
  • Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant. (uchicago.edu)
  • Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas. (uchicago.edu)
  • Dr. Dora Ho specializes in infection complications in immunocompromised patients, such as those with bone marrow transplant, solid organ transplant, cancers and other forms of immunodeficiency. (stanford.edu)
  • The 5-year probability of overall survival (OS) after allogeneic HCT was estimated to be 56% (95% confidence interval[CI], 55%- 57%) for patients receiving a transplant while in CR, and 22% (95% CI, 21%-23%) for those who were experiencing active disease. (apbmt.org)
  • In our program, transplants with age- adjusted conditioning are performed in patients until 70 years old. (scielo.org)
  • Also, there was an association between absence of radiographic signs of osseointegration of the structural graft and failure in this series of patients with large bone defects. (bvsalud.org)
CIBMTR1
  • She serves as a scientific director for the Center for International Blood & Marrow Transplant Research or CIBMTR, under their infection and immune reconstitution committee. (bmtinfonet.org)
Umbilical cord1
  • Umbilical cord blood transplant -- This is a type of allogeneic transplant. (medlineplus.gov)
Intensity2
  • Reduced intensity treatment, also called a mini transplant -- Lower doses of chemotherapy and radiation are given before a transplant. (medlineplus.gov)
  • Mini transplant or reduced-intensity therapy means chemotherapy and radiation in smaller doses while myeloablative or ablative therapy means high doses of radiation, chemotherapy, or combination. (yapitahealth.com)
Procedure3
Type of transplant2
  • The side effects of this type of transplant include increased risk of infections, excessive bleeding, graft-versus-host disease, etc. (bgsgleneaglesglobalhospitalbengaluru.com)
  • Additionally, it is important to consider the cost of the transplant, as it can vary depending on various factors, such as the type of transplant and the hospital. (yapitahealth.com)
Busulfan3
  • Adding venetoclax to fludarabine/busulfan RIC transplant for high risk MDS and AML is feasible, safe, and active. (harvard.edu)
  • Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease. (uchicago.edu)
  • This protocol consisted of a myeloablative conditioning (MAC) regimen containing cytarabine, busulfan, Cy combined with standard-dose ATG/G-CSF (the so-called Beijing protocol), and followed by low-dose PTCy (14.5 mg/kg on days 3 and 4 after HCT) for haplo-HCT recipients. (biomedcentral.com)
HSCT1
  • Method: We aimed to evaluate the temporal trends in HSCT transplant rates in Argentina. (bvsalud.org)
Harvest1
  • Bone marrow harvest -- This minor surgery is done under general anesthesia . (medlineplus.gov)
Engraftment1
  • Allogeneic stem cell transplant in renal failure: engraftment and prolonged survival, but high incidence of neurologic toxicity. (uchicago.edu)
Cohort1
  • When stopping rules were again met, the study advanced to the third cohort which included 100mg/kg Cy in divided doses on days 3 and 4 post-transplant. (nih.gov)
Prevention1
  • The second presentation was by Dr. Courtney Fitzhugh, M.D , Lasker Clinical Research Scholar, Laboratory of Early Sickle Mortality Prevention on the NIH Experience in Nonmyeloablative Allogeneic Transplant for SCD. (nih.gov)
Ablative1
  • Ablative (myeloablative) treatment -- High-dose chemotherapy, radiation, or both are given to kill any cancer cells. (medlineplus.gov)
Clinical1
  • Abstract Objective To evaluate the clinical and radiographic results and survival of the acetabular revision surgery of total hip arthroplasty with cemented implant without the use of reinforcement ring, associated with structural homologous bone grafting. (bvsalud.org)
Acute1
  • Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia. (mcw.edu)
Half-matched1
  • Therefore, the goal was to develop a nonmyeloablative haploidentical (or half-matched) protocol for adults with severe SCD. (nih.gov)
Cytarabine1
  • Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. (uchicago.edu)
Blood1
Recipients2
  • BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants. (uchicago.edu)
  • Pilot study of comprehensive geriatric assessment (CGA) in allogeneic transplant: CGA captures a high prevalence of vulnerabilities in older transplant recipients. (uchicago.edu)
Syndrome1
  • Defibrotide: Real World Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Stem Cell Transplant. (harvard.edu)
Infections1
Hospital1
Graft2
  • Radiographs were evaluated according to the classification of the acetabular bone defect, graft shape, and the presence of osseointegration. (bvsalud.org)
  • The failures did not correlate with the severity of the acetabular bone defect, thickness, or graft configuration. (bvsalud.org)
Predict1
  • This study evaluated the utility of a novel indicator, the Bone Marrow Quality Index (BMQI), to predict aGVHD. (bvsalud.org)
Cells1
  • 0.5 x 109 cells/kg and being transplanted in CR1 versus CR/PR from second-line therapy were identified as independent predictors for OS and PFS. (astct.org)
Disease1
  • The first step was to provide a curative option for the majority of adults with SCD that are not eligible for the standard transplant because of age and co-morbidities including heart, lung, and kidney disease. (nih.gov)